TRIM63 and pancreatic neoplasm: In contrast to skeletal muscle, which is targeted for degradation by the muscle-specific E3 ubiquitin ligases MuRF1 and Atrogin1/MAFbx [4], no upregulation of either of these E3 ligases was detected in human visceral SMCs treated with tumor organoid factors from cachectic pancreatic cancer patients.